These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38684433)

  • 21. Delayed diagnosis of TAFRO syndrome: A case report.
    Qiao Y; Zhang X; Xu R; Jia X; Wang Q
    Medicine (Baltimore); 2024 Aug; 103(31):e39148. PubMed ID: 39093747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [TAFRO syndrome with primary Sjogren's syndrome].
    Iwanaga N; Harada K; Tsuji Y; Kawahara C; Kurohama K; Izumi Y; Yoshida S; Fujikawa K; Ito M; Kawakami A; Migita K
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(5):478-484. PubMed ID: 27795506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver cirrhosis in a child associated with Castleman's disease: A case report.
    Kobayashi S; Inui A; Tsunoda T; Umetsu S; Sogo T; Mori M; Shinkai M; Fujisawa T
    World J Clin Cases; 2020 May; 8(9):1656-1665. PubMed ID: 32432144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case report.
    Zhou B; Tang C; Chen G; Jiang T; Shi X; Wang F
    Hematol Oncol; 2023 Apr; 41(2):285-290. PubMed ID: 34997628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
    Nishimura Y; Fajgenbaum DC; Pierson SK; Iwaki N; Nishikori A; Kawano M; Nakamura N; Izutsu K; Takeuchi K; Nishimura MF; Maeda Y; Otsuka F; Yoshizaki K; Oksenhendler E; van Rhee F; Sato Y
    Am J Hematol; 2021 Oct; 96(10):1241-1252. PubMed ID: 34265103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
    Kadoba K; Waki D; Nishimura K; Mukoyama H; Saito R; Murabe H; Yokota T
    Medicine (Baltimore); 2020 Oct; 99(42):e22793. PubMed ID: 33080751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the clinical characteristics of TAFRO syndrome and idiopathic multicentric Castleman disease in general internal medicine: a 6-year retrospective study.
    Nishimura Y; Hanayama Y; Fujii N; Kondo E; Otsuka F
    Intern Med J; 2020 Feb; 50(2):184-191. PubMed ID: 31211492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Siltuximab Monotherapy in Tafro Syndrome: A Case Report and Review of the Literature.
    Cordero L; Aguilar-Rodríguez F; Sandino J; Alonso M; Gutiérrez E
    J Nephrol; 2023 May; 36(4):1181-1185. PubMed ID: 36652167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment with Cyclosporin A in Tocilizumab-resistant TAFRO Syndrome.
    Yamaga Y; Tokuyama K; Kato T; Yamada R; Murayama M; Ikeda T; Yamakita N; Kunieda T
    Intern Med; 2016; 55(2):185-90. PubMed ID: 26781021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Computed tomography findings of early-stage TAFRO syndrome and associated adrenal abnormalities.
    Kurokawa R; Gonoi W; Yokota H; Isshiki S; Ohira K; Mizuno H; Kiguchi T; Inui S; Kurokawa M; Kato S; Matsuki M; Takeda T; Yokoyama K; Ota Y; Nakai Y; Maeda E; Mori H; Abe O
    Eur Radiol; 2020 Oct; 30(10):5588-5598. PubMed ID: 32440781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High proportion of TAFRO syndrome in Thai adult Castleman's disease patients: a 10-year experience.
    Owattanapanich W; Pholmoo W; Pongpruttipan T; Siritanaratkul N
    Ann Hematol; 2018 Jun; 97(6):1019-1026. PubMed ID: 29464312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.
    Kurose N; Mizutani KI; Kumagai M; Shioya A; Guo X; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Kida M; Yamada S
    Pathol Res Pract; 2019 Mar; 215(3):410-413. PubMed ID: 30642741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.
    Sakai K; Maeda T; Kuriyama A; Shimada N; Notohara K; Ueda Y
    Mod Rheumatol; 2018 May; 28(3):564-569. PubMed ID: 26886414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [HHV-8-positive Castleman's disease with rapidly progressing multiorgan failure mimicking TAFRO syndrome].
    Ide S; Ohara S; Uchida T; Inoue M; Hagihara M
    Rinsho Ketsueki; 2020; 61(10):1497-1501. PubMed ID: 33162447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [TAFRO syndrome and cutaneous necrotizing vasculitis].
    Maquet J; Bories E; Nogier MB; Beck C; Aizel G; Toledano A; Faguer S; Paricaud K; Pugnet G; Moulis G; Astudillo L; Sailler L
    Rev Med Interne; 2021 Feb; 42(2):134-139. PubMed ID: 33218790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dysmorphic megakaryocytes in TAFRO syndrome: A case series from a single institute.
    Maida S; Nakagawa H; Ureshino H; Kajihara K; Yamazaki S; Ichinohe T
    Blood Cells Mol Dis; 2024 Sep; 108():102870. PubMed ID: 38901333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy.
    Iwaki N; Sato Y; Takata K; Kondo E; Ohno K; Takeuchi M; Orita Y; Nakao S; Yoshino T
    J Clin Exp Hematop; 2013; 53(1):87-93. PubMed ID: 23801139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.
    Leurs A; Gnemmi V; Lionet A; Renaud L; Gibier JB; Copin MC; Hachulla E; Hatron PY; Launay D; Fajgenbaum D; Terriou L
    Front Immunol; 2019; 10():1489. PubMed ID: 31316523
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: A case report.
    Kakutani T; Nunokawa T; Chinen N; Tamai Y
    Medicine (Baltimore); 2022 Dec; 101(48):e32200. PubMed ID: 36482523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TAFRO Syndrome.
    Igawa T; Sato Y
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):107-118. PubMed ID: 29157612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.